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oRIGINAL ARTICLE
Background: Cytokeratin 19 and its soluble fragment CYFRA have 
been studied as markers that may be associated with response to 
therapy and survival in non–small-cell lung cancer (NSCLC). As 
a prospective correlative study of Cancer and Leukemia Group B 
30203, a randomized phase II trial of carboplatin/gemcitabine with 
eicosanoid modulators (celecoxib, zileuton, or both) in advanced 
NSCLC, serum CYFRA levels were obtained before and during 
treatment.
Methods: Serum CYFRA levels were measured at baseline and after 
the first cycle of treatment using an electrochemoluminescent assay. 
Paired specimens were available from 88 patients. The logarithms of 
the initial concentration and of the difference in concentrations were 
analyzed for association with overall survival (oS) and failure-free 
survival (FFS).
Results: Lower baseline CYFRA levels were associated with both 
longer oS and FFS (p , 0.0001 and p 5 0.0003). In addition, 
larger reductions in CYFRA levels correlated with longer oS and 
FFS (p 5 0.0255 and p 5 0.0068).
Conclusion: CYFRA and change in CYFRA were found to be reli-
able markers for response to chemotherapy for NSCLC; however, a 
precise threshold to mark response has yet to be determined.
Key Words: Lung cancer, CYFRA.
(J Thorac Oncol. 2012;7: 649–654)
Biologic markers have become essential in guiding the treatment of many cancers, such as prostate and ovarian 
cancer. Identification of these markers saves time, money, and 
radiation exposure. Various markers such as carcinoembry-
onic antigen, neuron-specific enolase, tissue polypeptide spe-
cific antigen, squamous cell carcinoma antigen, and cancer 
antigen 125 have been studied in terms of their prognostic 
or predictive implications in lung cancer or as a method of 
assessing response to therapy.1,2 However, to date, no serum 
marker is currently recommended for routine clinical prac-
tice in non–small-cell lung cancer (NSCLC). one of the most 
promising markers for NSCLC is the soluble fragment of 
cytokeratin 19. Simple epithelium, such as bronchial epithe-
lium, is composed of intermediate filaments that give the cell 
its structure and strength. In malignant tissues, the intermedi-
ate filament known as cytokeratin 19 and the C-terminus of 
cytokeratin 19 (CYFRA 21-1, CYFRA) are released into cir-
culation by a cleaving enzyme, caspase-3, and apoptosis.3 For 
almost two decades, research has evaluated whether the serum 
levels of these filaments may relate to prognosis. In 2003, 
Vollmer et al4 summarized the research done before 1999 
and reported a trial completed at four Cancer and Leukemia 
Group B (CALGB) institutions evaluating the levels of 
CYFRA in 58 patients with stage III and IV NSCLC treated 
with chemotherapy. In this study, higher initial CYFRA con-
centrations predicted a worse prognosis and the ratio of loga-
rithm of CYFRA before and after one cycle of chemotherapy 
correlated with prognosis. Both the initial natural logarithm 
of serum CYFRA and the presence of a less than 27% drop in 
CYFRA were significantly related to subsequent survival. As 
part of a prospective CALGB study evaluating chemotherapy 
and eicosanoid modulation in advanced NSCLC (CALGB 
30203), we sought to confirm these findings. The evaluation 
of CYFRA, including the statistical objectives, was prospec-
tively defined in the protocol.
PATIENTS AND METHODS
CALGB 30203 tested the concept of eicosanoid inhi-
bition in advanced lung cancer and has been previously 
reported.5 The hypothesis was that eicosanoid inhibition in 
addition to standard chemotherapy would potentially increase 
progression-free survival. Furthermore, the concept of single 
versus double pathway inhibition was tested with inhibitors of 
cyclooxygenase-2 and 5-lipoxygenase as both single agents 
and in combination. Patients with advanced NSCLC (stage 
IIIB [pleural effusion]/IV) with performance status (PS) 0 
to 2, and normal organ function were randomized to receive 
chemotherapy (carboplatin area under the curve 5 5.5, day 
1 and gemcitabine 1000 mg/m2 day 1, 8) with one of three 
eicosanoid modulating regimens: zileuton 600 mg four times 
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a day, celecoxib 400 mg two times a day, or both agents. Each 
participant signed an Institutional Review Board-approved, 
protocol-specific informed consent in accordance with Federal 
and institutional guidelines.
To evaluate CYFRA levels, blood was collected in a 7-ml 
red top tube, inverted 5 times, left at room temperature to clot 
for 30 minutes, and then spun at 1100 to 1330 g for 10 minutes 
in a swinging head rotor at 25°C. Serum was then removed and 
placed in a polypropylene tube and frozen to −20°C or colder. 
Shipment to the CALGB Pathology Coordinating office was 
done on dry ice. Analysis of CYFRA levels was conducted 
on specimens at first thaw. CYFRA levels in the serum were 
measured by using two monoclonal antibodies to sandwich the 
molecule, KS 19.1 and BM 19.21. one antibody was labeled 
with a Ruthenium complex, which is electrochemically lumi-
nescent, and the other with a magnetic particle. When the elec-
tric potential is applied to the molecules, light is produced and 
measured by a photomultiplier. The coefficient of variation is 2 
to 5%.2 Samples were analyzed at the University of Maryland 
by Dr. Christenson in a Clinical Laboratory Improvement 
Amendments (CLIA)-approved laboratory without knowledge 
of patient characteristics or outcomes.
Patient registration and clinical data were managed by 
the CALGB Statistical Center. The statistical analysis was 
performed at the CALGB Statistical Center. The balance of 
demographic and clinical variables across study arms was 
tested by 2 tests for categorical variables and Wilcoxon rank 
sum tests for continuous variables. Kaplan-Meier curves were 
used to characterize overall survival (oS) and failure-free sur-
vival (FFS), in which oS was defined as the time from study 
entry to the date of death resulting from any cause, and FFS 
was defined as the time from study entry to the date of dis-
ease progression or death, whichever came first. Finally, Cox 
regression analysis was used to assess the association of base-
line CYFRA and the change of cycle-1 CYFRA relative to the 
baseline with survival end points. The logarithmic concentra-
tion values of CYFRA were used as previous studies show 
them to have association with outcome and the logarithmic 
transformation also serves to reduce the influence of extreme 
CYFRA values. As the decrease of cycle-1 CYFRA value rel-
ative to its baseline is a posttreatment covariate, the survival 
end points (oS and FFS) for this analysis are redefined by 
starting time from the end date of cycle-1 chemotherapy.
RESULTS
CALGB 30203 enrolled 140 patients in less than 1 year 
and showed no difference in oS or FFS among the three arms. 
Adequate serum samples before therapy and after the first cycle 
were obtained for 88 of the 140 patients (63%). Table 1 shows 
patient characteristics of those patients in CALGB 30203 who 
had CYFRA concentrations analyzed. There were no signifi-
cant differences among the arms, and the population for which 
samples were obtained for this analysis was comparable to the 
entire study population.
Table 2 shows the median, mean, minimum, and maxi-
mum CYFRA levels in all three arms at baseline and after 
cycle 1 of chemotherapy. Baseline CYFRA levels ranged from 
0.44 to 204.2 ng/ml with a median CYFRA level of 4.18 ng/ml 
and a mean level of 12.9 ng/ml. A Kaplan-Meier survival plot 
was constructed comparing those with initial CYFRA levels 
TABLE 1. Baseline Patient Characteristics of the 88 Patients with Serum CYFRA Levels Analyzed
Characteristics
CYFRA Decrease # 27% 
(n 5 47)
CYFRA Decrease .27% 
(n 5 41)
Total
(n 5 88)
Sex
 Male 26 (55%) 28 (68%) 54 (61%)
 Female 21 (45%) 13 (32%) 34 (39%)
Age (yr)
 ,60 19 (40%) 21 (51%) 40 (46%)
 60–69 16 (34%) 14 (34%) 30 (34%)
 70 12 (26%) 6 (15%) 18 (21%)
 Median (min, max) 61 (41, 80) 59 (49, 81) 60 (41, 81)
Race
 White 38 (81%) 37 (90%) 75 (85%)
 Black or other 9 (19%) 4 (10%) 13 (15%)
Histology
 Adenocarcinoma 25 (53%) 19 (46%) 44 (50%)
 Squamous 12 (26%) 9 (22%) 21 (24%)
 Undifferentiated 10 (21%) 13 (32%) 23 (26%)
Performance status
 0 14 (30%) 13 (32%) 27 (31%)
 1 or 2 33 (70%) 28 (68%) 61 (69%)
Stage
 IIIB 5 (11%) 2 (5%) 7 (8%)
 IV 39 (83%) 37 (90%) 76 (86%)
 Recurrent 3 (6%) 2 (5%) 5 (6%)
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above and below the median. As shown in Figure 1, patients 
with initial CYFRA levels below the median had a statistically 
significant increase in their oS (p 5 0.0216). After log trans-
formation, higher baseline CYFRA correlated with worse oS 
and FFS (p , 0.0001 and p 5 0.003) (Table 3).
After cycle 1, the median CYFRA level remained steady 
at 4.3 but the mean CYFRA level fell to 7.1 (Wilcoxon signed 
rank test, p 5 0.0225, Table 2). After logarithmic transforma-
tion, a greater reduction in CYFRA from baseline to after 
cycle 1 correlated with longer overall and FFS (p 5 0.0255 
and p 5 0.0068) in the multivariate analysis after adjusting 
for age and baseline CYFRA (Model 1, Table 3). We also 
confirmed the prognostic value of a greater than 27% decline 
in CYFRA being associated with better oS or FFS survival 
(p 5 0.0028 and p 5 0.0074) (Table 3). This decline occurred 
in 41 of the 88 patients tested. our analysis also confirmed that 
a greater than 27% decline on a logarithmic scale is also the 
optimal cutoff point that yields the largest separation between 
the high versus low CYFRA-decline patients (Table 3). There 
were no statistically significant differences in CYFRA levels 
at cycle 1 (Wilcoxon rank sum test, p 5 0.3654) or changes 
from baseline to cycle 1 (Wilcox rank sum test, p 5 0.7791) 
related to the type of eicosanoid modulator employed. There 
was no relationship between a 27% decline in CYFRA and 
response (p 5 0.114).
Multivariate analysis that included age, sex, PS, and 
staging (IIIB versus IV) was performed. only age emerged as 
a significant factor. Data regarding smoking status were not 
collected. Logistic regression analysis (oR 5 1.62, 95% confi-
dence interval 1.09–2.40; p 5 0.0161) indicated that squamous 
FIGURE 1. Kaplan-Meier survival curve based on baseline CYFRA above and below the median value.
TABLE 2. CYFRA Concentrations (ng/ml)
Median, Mean (minimum, maximum)
CYFRA Decrease < 27% 
(n 5 47)
CYFRA Decrease .27%
(n 5 41)
Total
(n 5 88)
CYFRA baseline 3.7, 12.7
(0.72, 204.2)
4.7, 13.2
(0.44, 87.0)
4.2, 12.9
(0.44, 204.2)
Log CYFRA baseline 1.3, 1.5
(−0.33, 5.3)
1.5, 1.6
(−0.82, 4.5)
1.4, 1.6
(−0.82, 5.3)
CYFRA cycle 1 5.5, 10.4
(0.51, 54.4)
1.7, 3.2
(0.66, 13.6)
4.3, 7.1
(0.51, 54.4)
Log CYFRA cycle 1 1.7, 1.8
(−0.67, 4.0)
0.51, 0.83
(−0.42, 2.6)
1.5, 1.4
(−0.67, 4.0)
CYFRA baseline–
CYFRA cycle 1
−1.0, 2.2
(−28.9, 154.4)
2.4, 10.0
(−0.87, 78.8)
0.53, 5.9
(−28.9, 154.4)
Log (CYFRA baseline)–
Log (CYFRA cycle 1)
−0.30, −0.29
(−1.8, 1.4)
0.70, 0.77
(−0.89, 2.6)
0.21, 0.20
(−1.8, 2.6)
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patients had higher baseline CYFRA levels. However, there 
was no correlation between changes of CYFRA and histol-
ogy (oR 5 0.97, p 5 0.9068). In addition, no correlation 
was noted between baseline CYFRA and sex (p 5 0.1146), 
age (p 5 0.0635), race (p 5 0.1088), PS (p 5 0.1549), histol-
ogy (p 5 0.1512), stage IIIB versus IV (p 5 0.0765).
DISCUSSION
This study prospectively confirms in a multicenter trial 
that serum concentrations of CYFRA have prognostic value 
in advanced NSCLC. Higher baseline CYFRA concentrations 
portend worse oS and FFS. In addition, this trial confirmed 
the significance of the cut point of a 27% reduction in log 
CYFRA after chemotherapy in determining benefit from treat-
ment. other cut points, including 10 to 75% decline, worked 
almost equally well (data not shown).
This information may be useful in determining whether 
or not to continue a particular chemotherapy regimen. If con-
firmed, this would provide a simple and inexpensive approach 
to the assessment of response to treatment.
of note, these findings are qualitatively similar to those 
of others as summarized by Vollmer et al (studies before 1999) 
and in Table 4 (studies after 1999).4 Prior studies have found 
that CYFRA elevations have correlated with stage and pre-
dicted for recurrent disease after surgery and for inferior sur-
vival. The significance of the current trial is that the patients 
were part of a prospective multicenter trial employing stan-
dard entry criteria and a uniform chemotherapy regimen.
There are several limitations to the current study. The 
number of patients studied was relatively small. In addition, as 
all arms used eicosanoid modulation, the chemotherapy regi-
mens could be considered “nonstandard.” However, all patients 
received standard, platinum-based two-drug chemotherapy. In 
addition, both of the experimental agents studied, celecoxib 
and/or zileuton, are drugs that are commercially available and 
they (or similar drugs) are commonly prescribed for patients 
with lung cancer. Another potentially confounding factor is 
a possible difference in “bulk” of the disease, which was not 
clearly captured in the required data and for which there is 
no standardized approach. It is quite possible that CYFRA 
is a nonspecific marker for tumor burden. Furthermore, this 
study did not evaluate nor compare CYFRA to other possible 
serum markers that have been used, such as carcinoembryonic 
antigen.6
In the current landscape of markers for NSCLC, 
CYFRA is unlikely to have the strong prognostic or predictive 
value of epithelial growth factor receptor activating mutations 
or EML4/ALK translocations. However, it may ultimately find 
a role as an early marker of tumor responsiveness to therapy.
In summary, this study demonstrates the potential value 
of CYFRA 21-1 as both a prognostic marker in advanced 
NSCLC and an early indicator of response to chemotherapy. 
Further studies are warranted to compare the value of CYFRA 
to radiologic imaging in determining response.
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